Commercializing Your First Cell Or Gene Therapy (CGT): Developing Your Market Access Strategy

By Joe DePinto, head of cell, gene and advanced therapies, McKesson

Bringing a new cell or gene therapy (CGT) to market is a complex undertaking, especially for companies new to the field. Joe DePinto, Head of Cell, Gene and Advanced Therapies at McKesson, shares crucial steps for developing a robust market access strategy. This involves an interdisciplinary approach, integrating insights from clinical development, regulatory affairs, manufacturing, HEOR, pricing, and marketing to ensure commercial readiness. A well-defined target product profile and strategic selection of clinical trial sites are also key to ensuring accessibility for patients.

Discover how to navigate the complexities of commercializing your CGT and ensure it reaches the patients who need it. Read the full article to learn more about developing your market access strategy.